Rheumatology Therapeutics Market
A rising elderly population and increasing allocations for research and development of new drugs is what is serving to drive growth in the global rheumatology therapeutics market. This has led to the emergence of many new drugs. Their swift approvals by the appropriate authorities has also led to the growth in the market.
A report by Transparency Market Research uncovers after in-depth study that the global rheumatology therapeutics market will rise at a lackluster CAGR of 2.7% from 2017 to 2025 to become worth US$ 52.96 bn by 2025 from US$41.88 bn in 2016.
Read Report Overview:https://www.transparencymarketresearch.com/rheumatology-therapeutics-market.html
Depending upon the drug class, the key segments of the global rheumatology disorder market are disease modifying anti-rheumatic drugs (DMARDs), non-steroidal anti-inflammatory drugs (NSAID’s), corticosteroids, uric acid drugs, etc. The DMARDs, which is a group of medicines or combination of medicines used to treat rheumatic diseases by blocking the inflammation, accounts for maximum shaee in the market at present. They are categorized into two major types - biologic DMARDs and synthetic DMARDs.
The biologic DMARDs are mostly used for the treatment of various rheumatic diseases such as rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. The patent expiry of top brands such as Humira, however, is expected to deal a blow to the growth in the segment. Market pundits predict the challenge will eventually be overcome by the wide pipeline of other biologics such as interleukin-6. By rising at a 2.6% CAGR from 2017 to 2025, the segment is projected to pull in a revenue of US$45.06 bn by 2025 from US$35.83 bn in 2016. Azathioprine, cyclophosphamide, cyclosporine, and methotrexate are highly used synthetic DMARDs for the treatment of rheumatic diseases.
Obtain the Brochure of the Report:https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1494
In terms of growth rate, corticosteroids are anticipated to surpass all other segments by clocking a CAGR of 4.4% from 2017 to 2025. Rising at this rate, the segment is projected to pull in a revenue of US$1.22 bn by 2025. Their increasing use in developing countries will likely boost their demand.
Substantial Elderly Population Drives North America Market
From a geographical standpoint, North America accounts for a leading share in the global rheumatology therapeutics market because of a rapid rise in the elderly population, who are afflicted with different types of rheumatology disorders. In addition to that, adoption of biologics and biosimilars products for the treatment of moderate to severe rheumatoid arthritis and well-established healthcare facilities has also provided a major boost to the market in the region. Europe trails North America vis-à-vis market size. In terms of growth rate, however, Asia Pacific is predicted to lead. This is because of the significant proportion of population suffering from rheumatoid arthritis and osteoarthritis, increasing per capita healthcare expenditure and approvals of biosimilars for the treatment of several types of rheumatology disorders.
Perceive the Sample of the Report:https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1494
Prominent companies operating in the global rheumatology therapeutics market are AbbVie, Inc., Pfizer, Inc., Bristol-Myers Squibb Company, Merck & Co., Inc. etc. accounted for the major share in global rheumatology therapeutics market in 2016. The other global players operating in the market include Amgen, Inc., Janssen Biotech, Inc., Novartis AG, Genentech, Inc., Sanofi, and Takeda Pharmaceutical.
Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.
TMR’s data repository is continuously updated and revised by a team of research experts so that it always reflects the latest trends and information. With extensive research and analysis capabilities, Transparency Market Research employs rigorous primary and secondary research techniques to develop distinctive data sets and research material for business reports.
90 State Street, Suite 700
Albany, NY 12207
USA - Canada Toll Free: 866-552-3453
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Rheumatology Therapeutics Market here
News-ID: 1562671 • Views: 625
More Releases from Transparecny Market Research
Advanced Wound Care Management Market - Global Industry Analysis, Size, Share, G …
Advanced Wound Care Management Market - Overview The market for wound care is expanding significantly, due to increase in advancements in treating complex wounds. The advanced wound care market is anticipated to expand during the forecast period, as the products have been a promising solution for rapid recovery and wound healing. These products offer superior solution than traditional products by offering desired outcome and effectiveness in healing wounds. Increasing incidences of
Operating Room Equipment Market projected to expand at a CAGR of 6.4% from 2018 …
Transparency Market Research (TMR) has published a new report titled ‘Operating room equipment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018–2026.’ According to the report, the global operating room equipment market was valued at US$ 29,912.3 Mn in 2017. It is projected to expand at a CAGR of 6.4% from 2018 to 2026. Aging population and longer life-expectancy, increased awareness, and acceptance of advanced devices are
Hip Replacement Implants Market Size, Status, Scope and Growth Prospects
The global hip replacement implants market was valued at approximately US$ 7.0 Bn in 2017. It is projected to register a cumulative annual growth rate (CAGR) of over 3.5% from 2018 to 2026, according to a new report published by Transparency Market Research (TMR) titled ‘Hip Replacement Implants Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018–2026.’ Expansion of the health care industry, government initiatives, increase in
Global 3D Applications in Health Care Market Industry Analysis Size, Share, Tren …
The global 3D application in health care market is categorized on the basis of application and type. Systems and services are segments that fall under the types of 3D applications. Out of these two, the services segment is projected to dominate the market in the coming years due to increasing demand for 3D imaging devices in the health care organizations 3D technology has come up as a blessing for the health
More Releases for DMARDs
Rheumatoid Arthritis (RA) Drugs Market Report 2018: Segmentation by Drug Class ( …
Global Rheumatoid Arthritis (RA) Drugs market research report provides company profile for AbbVie, Biogen, Inc., Bristol-Myers Squibb, Celgene Corporation, Celltrion Inc., Johnson & Johnson, MedImmune, LLC, Merck & Co., Inc., Novartis International AG, Takeda Pharmaceutical Company Ltd. and Others. This market study includes data about consumer perspective, comprehensive analysis, statistics, market share, company performances (Stocks), historical analysis 2012 to 2017, market forecast 2018 to 2025 in terms of volume, revenue,
Seropositive Rheumatoid Arthritis Drug Market 2018 to 2023 Industry Overview by …
The Global Seropositive Rheumatoid Arthritis Drug market is expected to register a CAGR of 4.0% during the forecast period of 2018 to 2023. The Seropositive Rheumatoid Arthritis Drug is segmented by Drug Class , product, Treatment , application, end-user, and region. Arthritis means inflammation in a joint. The inflammation is characterized by swelling, pain, and redness within the joint. This type of arthritis is known to cause chronic inflammatory disorder in
Global Rheumatoid Arthritis Drug Market Outlook 2022 Report
“Global Rheumatoid Arthritis Drug Market Outlook 2022” report highlights: * Classification and Molecular Mechanism of Rheumatoid Arthritis Drugs * Synthetic DMARDs as Rheumatoid Arthritis Drug * Biological Agents as Rheumatoid Arthritis Drug * Global Market of Rheumatoid Arthritis Drug * Global Tendencies in Use of Antirheumatics * Global Rheumatoid Arthritis Drug Market Future Prospect Download Report Sample Weblink: https://www.kuickresearch.com/report-global-rheumatoid-arthritis-drug-market-outlook-2022.php For Report Sample Contact: email@example.com Table of Contents Antirheumatoids: Call of Rheumatoid Arthritis 1.1 Prologue towards
Global Rheumatoid Arthritis Drug Market Outlook 2022 Report Download
“Global Rheumatoid Arthritis Drug Market Outlook 2022” report gives comprehensive clinical and non-clinical insight on various trends associated with the rheumatoid arthritis drug market across the developed and developing market. Report helps to identify the basic classification and molecular mechanism of action of rheumatoid arthritis drugs available in the market. The top 5 leading DMARDs (Humira, Enbrel, Remicade, Simponi and Otezla) have dominated the overall anti-rheumatics market with
Download Sample Global Rheumatoid Arthritis Drug Market Outlook 2022
“Global Rheumatoid Arthritis Drug Market Outlook 2022” report highlights: Classification and Molecular Mechanism of Rheumatoid Arthritis Drugs Synthetic DMARDs as Rheumatoid Arthritis Drug Biological Agents as Rheumatoid Arthritis Drug Global Market of Rheumatoid Arthritis Drug Global Tendencies in Use of Antirheumatics Global Rheumatoid Arthritis Drug Market Future Prospect For Report Sample Contact: firstname.lastname@example.org Report Weblink:https://www.kuickresearch.com/report-global-rheumatoid-arthritis-drug-market-outlook-2022.php Table of Contents Antirheumatoids: Call of Rheumatoid Arthritis 1.1 Prologue towards Rheumatoid Arthritis 1.2 Obtainable Treatment for Rheumatoid Arthritis
Rheumatoid Arthritis Drug Market Rheumatoid Arthritis Clinical Pipeline Report 2 …
For Report Sample Contact: email@example.com or +91-11-47067990 Report Table of Contents Antirheumatoids: Call of Rheumatoid Arthritis 1.1 Prologue towards Rheumatoid Arthritis 1.2 Obtainable Treatment for Rheumatoid Arthritis Molecular Mechanism of Antirheumatoids 2.1 Purpose of DMARDs in Rheumatoid Arthritis 2.2 Role of Biological Agents in Rheumatoid Arthritis 2.2.1 TNF- Inhibitors 2.2.2 Interleukin -1 and IL-6 Blockers Classification of Rheumatoid Arthritis Drugs 3.1